JNJ-87189401
JNJ-87189401 is an experimental costimulatory agent from Janssen Research & Development in phase 3 trials for prostate cancer, aimed at PSMA.
Overview
JNJ-87189401 is a costimulatory agent developed by Janssen Research & Development. Its target is PSMA (the sponsor names PSMA / CD28). The sponsor states: A PSMA-CD28 costimulatory agent intended to enhance T-cell activation via PSMA engagement plus CD28 costimulation. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07164443 (A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)), in prostate cancer. The largest, NCT07164443, plans to enrol 1203 participants with primary completion expected 2028-08-18. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas · Lines of therapy.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"JNJ-87189401" OR ABSTRACT:"JNJ-87189401") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about JNJ-87189401, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentFPI-2265
Shares PSMA, Prostate cancer and the tags pipeline, ctgov-ingest.
- TreatmentHRS-4357
Shares PSMA, Prostate cancer and the tags pipeline, ctgov-ingest.
- TreatmentINO-5401
Shares PSMA and the tags pipeline, ctgov-ingest.
- TreatmentAAA817
Shares PSMA, Prostate cancer and the tags pipeline, ctgov-ingest.
- TreatmentCetrelimab
Shares Johnson & Johnson, Prostate cancer and the tags pipeline, ctgov-ingest.
- TreatmentBleximenib
Shares Johnson & Johnson and the tags pipeline, ctgov-ingest.
- TreatmentJNJ-90301900
Shares Johnson & Johnson and the tags pipeline, ctgov-ingest.
- TreatmentJNJ-90014496
Shares Johnson & Johnson and the tags pipeline, ctgov-ingest.